跳至主要内容
临床试验/ISRCTN13477304
ISRCTN13477304进行中(未招募)未知

PAINSTORM: Partnership for Assessment and Investigation of NeuP: Studies Tracking Outcomes, Risks and Mechanisms

niversity of Dundee0 个研究点目标入组 200 人开始时间: 2022年11月15日最近更新:
适应症

试验速览

阶段
未知
状态
进行中(未招募)
发起方
入组人数
200

研究概览

简要总结

暂无简介。

研究设计

研究类型
Observational

入排标准

性别
All

入选标准

  • 1. 18 years or older
  • 2. Planned course of potentially neurotoxic chemotherapy for the treatment of cancer. This includes the following:
  • 2.1. Platinum drugs
  • 2.2. Taxanes
  • 2.3. Vinca alkaloids
  • 2.4. Epothilones
  • 2.5. Proteasome inhibitors
  • 2.6. Thalidomide
  • 2.7. Vedotin-based drugs
  • 2.8. Checkpoint inhibitors

排除标准

  • 1. Incapacity to give consent or to complete the study questionnaires due to insufficient language command or mental deficiencies, in the opinion of the investigator.
  • 2. Functional impairment - ECOG Performance Status Scale great than or equal to 3 at baseline.
  • 3. Concurrent clinically defined severe physical or psychiatric disorders that would preclude accurate phenotyping.
  • 4. Moderate to severe pain from other causes that may confound assessment or reporting of pain if unable to differentiate from CIPN.
  • 5. Patients who are in the opinion of the investigator, or treating oncology team, unsuitable for participation in the study.

研究者

发起方
niversity of Dundee

相似试验

Study investigating the impact, risk and mechanisms... | 临床试验